Neratinib
-
Catalog number2023-25
-
PricePlease ask
-
Size25 mg
-
-
Alternative_nameHKI-272
-
DescriptionCell-permeable. A second-generation inhibitor of the ErbB family of receptor kinases. Neratinib acts as an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. It inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro.
-
CAS Number698387-09-6
-
Structure AvailableYes
-
Salt FormNo
-
Molecular FormulaC₃₀H₂₉ClN₆O₃
-
Molecular Weight557.04
-
Cell PermeableYes
-
Purity≥98% by HPLC
-
SolubilitiesDMSO (~ 2 mg/ml)
-
HandlingProtect from air and moisture
-
Tag LineA potent erbB family receptor tyrosine kinase inhibitor
-
Storage Condition-20°C
-
Shipping Conditiongel pack
-
Shelf Life24 months
-
MDL NumberMFCD09752958
-
PubChem CID9915743
-
SMILESCCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C= CCN(C)C
-
InChiInChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2) 3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33- 22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
-
InChi KeyJWNPDZNEKVCWMY-VQHVLOKHSA-N
-
MSDS AvailableYes
-
Gene target
-
Short nameNeratinib
-
Alternative nameNeratinib
-